Presentation on NurOwn Phase 3 data demonstrating evidence of biological effect in ALS; Biomarker data reinforce clinical outcomes NEW YORK, Nov. 17, 2023 /PRNewswire/ -- BrainStorm Cell...

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the third quarter ended...

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold a conference call on Tuesday, November...

- Resource consumption will be reduced by 50% to accelerate ALS development - Plans underway for registrational Phase 3b U.S. clinical trial for NurOwn in ALS NEW YORK, Oct. 24, 2023 /PRNewswire/...

- Path forward for ALS is a registrational Phase 3b U.S. clinical trial - - Biologics License Application to be withdrawn without prejudice - - Conference call and webcast at 8:30am ET today - NEW...

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the outcome of the U.S. Food and Drug...

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that Nasdaq has halted trading of the...

FDA advisory committee (ADCOM) meeting to discuss NurOwn® for Amyotrophic Lateral Sclerosis (ALS) scheduled for September 27, 2023 BrainStorm's Biologics License Application (BLA) for NurOwn has...

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold a conference call to update...

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) (the "Company"), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it has entered into a...